|
1
|
Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW and Newton CR: Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. Epilepsia. 51:883–890. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shorvon SD, Andermann F and Guerrini R: The causes of epilepsy. Cambridge University Press, Cambridge, 2011.
|
|
3
|
Manford M: Recent advances in epilepsy. J Neurol. 264:1811–1824. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Liu G, Slater N and Perkins A: Epilepsy: Treatment options. Am Fam Physician. 96:87–96. 2017.PubMed/NCBI
|
|
5
|
Felton EA and Cervenka MC: Dietary therapy is the best option for refractory nonsurgical epilepsy. Epilepsia. 56:1325–1329. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
D'Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP and da Conceição PO: Ketogenic diet and epilepsy: What we know so far. Front Neurosci. 13(5)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Thijs RD, Surges R, O'Brien TJ and Sander JW: Epilepsy in adults. Lancet. 393:689–701. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, et al: Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 57:538–548. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N and Tytgat D: Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 57:201–209. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mula M: Brivaracetam for the treatment of epilepsy in adults. Expert Rev Neurother. 14:361–365. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Malawska B and Kulig K: Brivaracetam: A new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs. 17:361–369. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li-Na Z, Deng C, Hai-Jiao W, Da X, Ge T and Ling L: Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy. Epilepsy Res. 139:60–72. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhu LN, Chen D, Xu D, Tan G, Wang HJ and Liu L: Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison. Seizure. 51:121–132. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S and Benedetto U: Tolerability of new antiepileptic drugs: A network meta-analysis. Eur J Clin Pharmacol. 73:811–817. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Arnold S, Badalamenti V, Diaz A, Gasalla T, McShea C and Whitesides J: Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, phase III studies. Epilepsy Res. 141:73–82. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME and Lu S: Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 55:57–66. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
French JA, Costantini C, Brodsky A and von Rosenstiel P: Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial. Neurology. 75:519–525. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W and Stalvey T: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 56:1890–1898. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME and Lu S: Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 55:38–46. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ and Welch VA (editors): Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. htttps://www.training.cochrane.org/handbook.
|
|
21
|
Julian PTH, Douglas GA, Peter CG, Peter J, David M, Andrew DO, Jelena S, Kenneth FS and Laura W: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal. 343:889–893. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kwan P, Schachter SC and Brodie MJ: Drug-resistant epilepsy. N Eng J Med. 365:919–926. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Agrawal N and Mula M: Treatment of psychoses in patients with epilepsy: An update. Ther Adv Psychopharmacol. 9(2045125319862968)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Stafstrom CE and Carmant L: Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harb Perspect Med. 5(a022426)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S and Tacconi FM: Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. Br J Clin Pharmacol. 83:1873–1879. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nowak M, Bauer S, Schlegel K, Stei S, Allenhöfer L, Waschbisch A, Tackenberg B, Höllerhage M, Höglinger GU, Wegner S, et al: Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes. Seizure. 22:462–466. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Erbaş O, Yeniel AÖ, Akdemir A, Ergenoğlu AM, Yilmaz M, Taskiran D and Peker G: The beneficial effects of levetiracetam on polyneuropathy in the early stage of sepsis in rats: Electrophysiological and biochemical evidence. J Invest Surg. 26:312–318. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Itoh K, Ishihara Y, Komori R, Nochi H, Taniguchi R, Chiba Y, Ueno M, Takata-Tsuji F, Dohgu S and Kataoka Y: Levetiracetam treatment influences blood-brain barrier failure associated with angiogenesis and inflammatory responses in the acute phase of epileptogenesis in post-status epilepticus mice. Brain Res. 1652:1–13. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Selçuk AA: A guide for systematic reviews: PRISMA. Turk Arch Otorhinolaryngol. 57:57–58. 2019.PubMed/NCBI View Article : Google Scholar
|
